Machina Capital S.A.S. Sells 7,580 Shares of Globe Life Inc. $GL

Machina Capital S.A.S. cut its stake in shares of Globe Life Inc. (NYSE:GL) by 65.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 4,078 shares of the company’s stock after selling 7,580 shares during the quarter. Machina Capital S.A.S.’s holdings in Globe Life were worth $583,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Synergy Asset Management LLC increased its position in shares of Globe Life by 1,022.7% during the third quarter. Synergy Asset Management LLC now owns 100,603 shares of the company’s stock worth $14,240,000 after buying an additional 91,642 shares during the period. SteelPeak Wealth LLC bought a new stake in Globe Life during the third quarter valued at $2,985,000. Retirement Systems of Alabama acquired a new stake in Globe Life during the 3rd quarter worth about $2,470,000. MGO One Seven LLC bought a new position in shares of Globe Life in the 3rd quarter worth about $1,364,000. Finally, Inspire Investing LLC acquired a new position in shares of Globe Life in the 3rd quarter valued at about $1,062,000. Institutional investors and hedge funds own 81.61% of the company’s stock.

Key Headlines Impacting Globe Life

Here are the key news stories impacting Globe Life this week:

• Positive Sentiment: JPMorgan raised its price target to $181 and kept an “overweight” rating, implying roughly ~23% upside from current levels — a bullish analyst signal that can support further buying. Benzinga
• Positive Sentiment: Company earnings call and transcripts highlighted resilient growth and improving operating income versus prior year, reinforcing management’s message that core business metrics remain healthy. Globe Life Earnings Call Highlights
• Neutral Sentiment: Globe Life reported Q4 net operating income of $3.39 per diluted share (versus $3.14 a year ago) and revenue of $1.52B (+3.6% YoY). The results show year‑over‑year improvement but were slightly off Wall Street estimates. PR Newswire Release
• Negative Sentiment: Q4 EPS missed consensus by ~$0.05 ($3.39 vs $3.44) and revenue narrowly trailed estimates — items that can temper upside after the initial reaction. Zacks: Earnings & Revenues Lag
• Negative Sentiment: Management set FY2026 EPS guidance of $14.95–$15.65, which sits around (and slightly below) consensus (~$15.03) — a modestly cautious guide that could limit upside if investors were expecting a higher midpoint. MarketBeat: Q4 Results & Guidance

Wall Street Analysts Forecast Growth

Several research firms recently commented on GL. JPMorgan Chase & Co. raised their target price on Globe Life from $180.00 to $181.00 and gave the stock an “overweight” rating in a research note on Thursday. Weiss Ratings downgraded shares of Globe Life from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, January 14th. Keefe, Bruyette & Woods boosted their target price on shares of Globe Life from $160.00 to $162.00 and gave the company an “outperform” rating in a research report on Tuesday, October 28th. Wells Fargo & Company cut their target price on shares of Globe Life from $172.00 to $170.00 and set an “overweight” rating on the stock in a research note on Friday, October 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $167.00 price target on shares of Globe Life in a research note on Friday, November 21st. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $168.56.

Globe Life Trading Up 1.6%

NYSE:GL opened at $147.15 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 0.07 and a quick ratio of 0.07. Globe Life Inc. has a one year low of $109.38 and a one year high of $152.71. The company has a market cap of $11.71 billion, a PE ratio of 10.45 and a beta of 0.47. The firm has a 50-day moving average of $139.14 and a 200-day moving average of $137.79.

Globe Life (NYSE:GL) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $3.39 earnings per share for the quarter, missing the consensus estimate of $3.44 by ($0.05). The business had revenue of $1.52 billion during the quarter, compared to the consensus estimate of $1.53 billion. Globe Life had a net margin of 19.37% and a return on equity of 21.75%. Globe Life’s revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business posted $3.14 EPS. Globe Life has set its FY 2026 guidance at 14.950-15.650 EPS. As a group, equities research analysts expect that Globe Life Inc. will post 13.87 EPS for the current fiscal year.

Insider Activity

In related news, CEO Frank M. Svoboda sold 9,379 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $140.43, for a total transaction of $1,317,092.97. Following the completion of the sale, the chief executive officer owned 35,868 shares in the company, valued at approximately $5,036,943.24. This represents a 20.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.51% of the stock is currently owned by insiders.

Globe Life Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.